Company news
Prescient Therapeutics Limited (ASX:PTX) news
Prescient Therapeutics Limited news releases on 6ix. Latest, Sep 23, 2026: PTX Successfully Completes $6m Raise Via SPP and Placement
Press releases & updates
PTX Successfully Completes $6m Raise Via SPP and Placement
September 22, 2026
PTX-100 CTCL Phase 2a study reaches review milestone
September 2, 2026
Prescient Therapeutics Opens SPP to Raise $7m Today
August 25, 2026
Appendix 4E and 2026 Annual Report
August 20, 2026
June 2026 Quarterly Update and Appendix 4C
July 26, 2026
March 2026 Quarterly Update and Appendix 4C
April 29, 2026
Appendix 4D and Half Year Financial Report
February 24, 2026
December 2025 Quarterly Update and Appendix 4C
January 29, 2026
PTX secures EU Authorisation to commence PTX-100 Trial
December 14, 2025
PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
November 18, 2025
September Quarterly Updated and Appendix 4C
October 9, 2025
Appendix 4E and 2025 Annual Report
August 20, 2025
Prescient successfully completes $3 million Placement
July 31, 2025
June 2025 Quarterly Update and Appendix 4C
July 30, 2025
Prescient announces results of SPP & Launches Placement
July 29, 2025
Trading Halt
July 28, 2025
Prescient Therapeutics - Extension of Share Purchase Plan
July 22, 2025
PTX Opens First U.S. Site for PTX-100 Phase 2a Trial
July 15, 2025
Prescient Therapeutics Extends Share Purchase Plan
July 14, 2025
Prescient Therapeutics Opens Share Purchase Plan
July 1, 2025
Prescient Therapeutics Launches Share Purchase Plan for $7m
June 30, 2025
First Patient dosed for PTX-100 Phase 2a Study
May 26, 2025
March 2025 Quarterly Update and Appendix 4C
April 28, 2025
PTX-100 receives U.S. FDA Fast Track Designation
April 15, 2025
PTX Opens First Clinical site for PTX-100 Phase 2a Study
March 25, 2025
December 2024 Quarterly Update and Appendix 4C - amended
January 31, 2025
December 2024 Quarterly Update and Appendix 4C
January 30, 2025
US FDA allows PTX-100 Ph2 trial
December 22, 2024
Appointment of Chief Executive Officer
December 17, 2024
September 2024 Quarterly Update and Appendix 4C
October 30, 2024
Prescient CEO to step down in early 2025
September 11, 2024
Appendix 4E and 2024 Annual Report
August 26, 2024
June 2024 Quarterly Update and Appendix 4C
July 31, 2024
March 2024 Quarterly Update and Appendix 4C
April 30, 2024
December 2023 Quarterly Update and Appendix 4C
January 31, 2024
PTX-100 Ph1b results show excellent safety & efficacy in TCL
December 10, 2023
September 2023 Quarterly Update and Appendix 4C
October 30, 2023
Appendix 4E and 2023 Annual Report
August 24, 2023
June 2023 Quarterly Update and Appendix 4C
July 26, 2023
March 2023 Quarterly Update and Appendix 4C
April 27, 2023
Continued promising results in PTX-100 TCL trial
March 15, 2023
FDA grants broader orphan drug status to PTX100 for TCLs
March 8, 2023
December 2022 Quarterly Update and Appendix 4C
January 25, 2023
AGM Presentation
November 29, 2022
September 2022 Quarterly Update and Appendix 4C
October 30, 2022
PTX-100 Trial Update
October 24, 2022
Placement Results
October 10, 2022
SPP Results and Placement
October 6, 2022
PTX unveils CellPryme-A to boost CAR-T performance
September 22, 2022
PTX strategic collaboration with MD Anderson Cancer Center
September 6, 2022